Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14826MR)

This product GTTS-WQ14826MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14826MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10789MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ3808MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ12587MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ12856MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ6120MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ12096MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ11519MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ11937MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW